SNSE
Faeth Therapeutics, Inc.
Price Chart
Latest Quote
$13.85
+0.00 (+0.00%)
Current Price
| Previous Close | $13.85 |
| Open | $15.21 |
| Day High | $16.52 |
| Day Low | $13.76 |
| Volume | 219,467 |
Stock Information
| Shares Outstanding | 1.34M |
| Total Debt | $1.04M |
| Cash Equivalents | $202.79M |
| Net Income | $-184.46M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $18.59M |
| EPS (TTM) | $-142.72 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-182.26M |
| Income | $-184.46M |
| Book/sh | $-102.43 |
| Cash/sh | $151.12 |
| Employees | 29 |
Financial Ratios
| Quick Ratio | 14.29 |
| Current Ratio | 14.39 |
Returns & Margins
| ROA | -95.24% |
Ownership
| Insider Ownership | 28.29% |
| Institutional Ownership | 153.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.49 |
| P/B | -0.14 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $51.67 |
Technical Indicators
| SMA20 | $15.70 |
| SMA50 | $22.13 |
| SMA200 | $16.41 |
| RSI | 40.42 |
| ATR | 2.7586 |
| Shares Float | 812K |
| Short Float | 84.60% |
| Short Ratio | 23.85 |
| Volatility | -0.23 |
| Rel Volume | 0.95 |
Performance History
| Week | +62.84% |
| Month | +4.77% |
| Quarter | -42.49% |
| 6 Months | +117.45% |
| YTD | +82.17% |
| Year | +168.24% |
| 3 Years | -34.93% |
| 5 Years | -92.67% |
| 10 Years | -95.35% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $17.57 | 65,675 |
| 2026-06-17 | $16.65 | 166,959 |
| 2026-06-16 | $14.53 | 155,542 |
| 2026-06-15 | $14.18 | 219,728 |
| 2026-06-12 | $13.10 | 57,909 |
| 2026-06-11 | $10.79 | 71,197 |
| 2026-06-10 | $11.41 | 52,050 |
| 2026-06-09 | $12.63 | 55,633 |
| 2026-06-08 | $13.00 | 49,551 |
| 2026-06-05 | $14.65 | 50,833 |
| 2026-06-04 | $16.60 | 36,794 |
| 2026-06-03 | $15.85 | 44,500 |
| 2026-06-02 | $16.09 | 60,568 |
| 2026-06-01 | $19.79 | 66,891 |
| 2026-05-29 | $21.14 | 69,932 |
| 2026-05-28 | $17.59 | 40,488 |
| 2026-05-27 | $16.65 | 53,510 |
| 2026-05-26 | $16.47 | 27,180 |
| 2026-05-22 | $17.79 | 21,119 |
| 2026-05-21 | $17.56 | 15,960 |
| 2026-05-20 | $17.58 | 26,411 |
| 2026-05-19 | $16.77 | 51,490 |
About Faeth Therapeutics, Inc.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $32,000 | $90,000 | $144,000 | $219,000 |
| Total Expenses | $22,288,000 | $31,663,000 | $37,064,000 | $50,188,000 |
| Other Income Expense | $-4,000 | $-954,000 | $-517,000 | $36,000 |
| Other Non Operating Income Expenses | $-4,000 | $-3,000 | $-215,000 | $36,000 |
| Net Non Operating Interest Income Expense | $1,207,000 | $2,460,000 | $3,480,000 | $1,564,000 |
| Interest Expense Non Operating | $32,000 | $90,000 | $144,000 | $219,000 |
| Operating Expense | $22,288,000 | $31,663,000 | $37,064,000 | $50,188,000 |
| General And Administrative Expense | $11,328,000 | $13,036,000 | $18,765,000 | $19,805,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Net Interest Income | $1,207,000 | $2,460,000 | $3,480,000 | $1,564,000 |
| Interest Income | $1,239,000 | $2,550,000 | $3,624,000 | $1,783,000 |
| Normalized Income | $-21,085,000 | $-29,206,000 | $-33,799,000 | $-48,588,000 |
| Net Income From Continuing And Discontinued Operation | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Total Operating Income As Reported | $-22,288,000 | $-32,614,000 | $-37,064,000 | $-50,188,000 |
| Net Income Common Stockholders | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Net Income | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Net Income Including Noncontrolling Interests | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Net Income Continuous Operations | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Pretax Income | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Special Income Charges | $0 | $-951,000 | $-302,000 | $0 |
| Interest Income Non Operating | $1,239,000 | $2,550,000 | $3,624,000 | $1,783,000 |
| Operating Income | $-22,288,000 | $-31,663,000 | $-37,064,000 | $-50,188,000 |
| Per Share | ||||
| Diluted EPS | $-16.72 | $-24.00 | $-24.40 | $-31.60 |
| Basic EPS | $-16.72 | $-24.00 | $-24.40 | $-31.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-20,914,000 | $-27,794,000 | $-32,304,000 | $-47,022,000 |
| Total Unusual Items | $0 | $-951,000 | $-302,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-951,000 | $-302,000 | $0 |
| Reconciled Depreciation | $139,000 | $1,322,000 | $1,351,000 | $1,347,000 |
| EBITDA (Bullshit earnings) | $-20,914,000 | $-28,745,000 | $-32,606,000 | $-47,022,000 |
| EBIT | $-21,053,000 | $-30,067,000 | $-33,957,000 | $-48,369,000 |
| Diluted Average Shares | $1,260,772 | $1,255,861 | $1,397,642 | $1,535,164 |
| Basic Average Shares | $1,260,772 | $1,255,861 | $1,397,642 | $1,535,164 |
| Diluted NI Availto Com Stockholders | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Impairment Of Capital Assets | $0 | $951,000 | $0 | - |
| Research And Development | $10,960,000 | $18,627,000 | $18,299,000 | $30,383,000 |
| Selling General And Administration | $11,328,000 | $13,036,000 | $18,765,000 | $19,805,000 |
| Other Gand A | $11,328,000 | $13,036,000 | $18,765,000 | $19,805,000 |
| Gain On Sale Of Ppe | - | $0 | $-302,000 | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $18,592,000 | $38,386,000 | $64,895,000 | $103,407,000 |
| Total Assets | $22,902,000 | $45,361,000 | $74,374,000 | $118,375,000 |
| Total Non Current Assets | $1,395,000 | $3,432,000 | $7,124,000 | $9,786,000 |
| Other Non Current Assets | $18,000 | $48,000 | $86,000 | $63,000 |
| Current Assets | $21,507,000 | $41,929,000 | $67,250,000 | $108,589,000 |
| Other Current Assets | $92,000 | $120,000 | $325,000 | $344,000 |
| Prepaid Assets | $231,000 | $474,000 | $1,168,000 | $1,129,000 |
| Cash Cash Equivalents And Short Term Investments | $21,184,000 | $41,335,000 | $65,757,000 | $107,116,000 |
| Cash And Cash Equivalents | $8,668,000 | $9,994,000 | $13,011,000 | $17,795,000 |
| Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,509,000 | $3,845,000 | $6,208,000 | $8,033,000 |
| Long Term Debt And Capital Lease Obligation | $59,000 | $1,527,000 | $3,769,000 | $5,902,000 |
| Current Debt And Capital Lease Obligation | $1,450,000 | $2,318,000 | $2,439,000 | $2,131,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,310,000 | $6,975,000 | $9,479,000 | $14,968,000 |
| Total Non Current Liabilities Net Minority Interest | $59,000 | $1,527,000 | $3,836,000 | $5,902,000 |
| Current Liabilities | $4,251,000 | $5,448,000 | $5,643,000 | $9,066,000 |
| Other Current Liabilities | $77,000 | $126,000 | - | - |
| Payables And Accrued Expenses | $1,404,000 | $1,122,000 | $1,694,000 | $4,473,000 |
| Payables | $689,000 | $244,000 | - | - |
| Accounts Payable | $689,000 | $244,000 | - | - |
| Other Non Current Liabilities | - | - | $67,000 | - |
| Equity | ||||
| Common Stock Equity | $18,592,000 | $38,386,000 | $64,895,000 | $103,407,000 |
| Total Equity Gross Minority Interest | $18,592,000 | $38,386,000 | $64,895,000 | $103,407,000 |
| Stockholders Equity | $18,592,000 | $38,386,000 | $64,895,000 | $103,407,000 |
| Gains Losses Not Affecting Retained Earnings | $1,000 | $-13,000 | $-209,000 | $-1,004,000 |
| Other Equity Adjustments | $1,000 | $-13,000 | $-209,000 | $-1,004,000 |
| Retained Earnings | $-283,137,000 | $-262,052,000 | $-231,895,000 | $-197,794,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $1,261,685 | $1,259,029 | $1,251,509 | $1,538,208 |
| Share Issued | $1,261,685 | $1,259,029 | $1,251,509 | $1,538,208 |
| Tangible Book Value | $18,592,000 | $38,386,000 | $64,895,000 | $103,407,000 |
| Invested Capital | $18,592,000 | $38,386,000 | $64,895,000 | $103,407,000 |
| Working Capital | $17,256,000 | $36,481,000 | $61,607,000 | $99,523,000 |
| Capital Lease Obligations | $1,509,000 | $3,845,000 | $6,208,000 | $8,033,000 |
| Total Capitalization | $18,592,000 | $38,386,000 | $64,895,000 | $103,407,000 |
| Additional Paid In Capital | $301,728,000 | $300,451,000 | $296,996,000 | $302,202,000 |
| Capital Stock | $0 | $0 | $3,000 | $3,000 |
| Common Stock | $0 | $0 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $59,000 | $1,527,000 | $3,769,000 | $5,902,000 |
| Current Capital Lease Obligation | $1,450,000 | $2,318,000 | $2,439,000 | $2,131,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,320,000 | $1,882,000 | $1,510,000 | $2,462,000 |
| Current Accrued Expenses | $715,000 | $878,000 | - | - |
| Net PPE | $1,377,000 | $3,384,000 | $7,038,000 | $9,723,000 |
| Accumulated Depreciation | $-540,000 | $-1,496,000 | $-1,727,000 | $-1,443,000 |
| Gross PPE | $1,917,000 | $4,880,000 | $8,765,000 | $11,166,000 |
| Leases | $253,000 | $253,000 | $253,000 | $253,000 |
| Other Properties | $1,295,000 | $4,273,000 | $7,980,000 | $10,381,000 |
| Machinery Furniture Equipment | $369,000 | $354,000 | $532,000 | $532,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $12,516,000 | $31,341,000 | $52,746,000 | $89,321,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-20,469,000 | $-24,816,000 | $-32,203,000 | $-39,347,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-20,453,000 | $-24,670,000 | $-32,023,000 | $-39,026,000 |
| Cash Flow From Continuing Operating Activities | $-20,453,000 | $-24,670,000 | $-32,023,000 | $-39,026,000 |
| Operating Gains Losses | - | - | $302,000 | $-30,000 |
| Investing Activities | ||||
| Capital Expenditure | $-16,000 | $-146,000 | $-180,000 | $-321,000 |
| Investing Cash Flow | $19,772,000 | $22,440,000 | $38,412,000 | $49,949,000 |
| Cash Flow From Continuing Investing Activities | $19,772,000 | $22,440,000 | $38,412,000 | $49,949,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,000 | $0 | $-10,384,000 | $0 |
| Financing Cash Flow | $-645,000 | $-787,000 | $-11,173,000 | $-287,000 |
| Cash Flow From Continuing Financing Activities | $-645,000 | $-787,000 | $-11,173,000 | $-287,000 |
| Net Other Financing Charges | $-3,000 | $-10,000 | $-76,000 | - |
| Net Common Stock Issuance | $-1,000 | $0 | $-10,384,000 | $0 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-790,000 | $-811,000 | $-761,000 | $-629,000 |
| Issuance Of Debt | $142,000 | $0 | - | - |
| End Cash Position | $8,668,000 | $9,994,000 | $13,011,000 | $17,795,000 |
| Beginning Cash Position | $9,994,000 | $13,011,000 | $17,795,000 | $7,159,000 |
| Changes In Cash | $-1,326,000 | $-3,017,000 | $-4,784,000 | $10,636,000 |
| Proceeds From Stock Option Exercised | $7,000 | $34,000 | $48,000 | $342,000 |
| Common Stock Payments | $-1,000 | $0 | $-10,384,000 | $0 |
| Net Issuance Payments Of Debt | $-648,000 | $-811,000 | $-761,000 | $-629,000 |
| Net Long Term Debt Issuance | $-648,000 | $-811,000 | $-761,000 | $-629,000 |
| Long Term Debt Payments | $-790,000 | $-811,000 | $-761,000 | $-629,000 |
| Long Term Debt Issuance | $142,000 | $0 | - | - |
| Net Investment Purchase And Sale | $19,538,000 | $22,586,000 | $38,426,000 | $50,255,000 |
| Sale Of Investment | $44,693,000 | $67,181,000 | $59,575,000 | $97,124,000 |
| Purchase Of Investment | $-25,155,000 | $-44,595,000 | $-21,149,000 | $-46,869,000 |
| Net PPE Purchase And Sale | $234,000 | $-146,000 | $-14,000 | $-306,000 |
| Sale Of PPE | $250,000 | $0 | $166,000 | $15,000 |
| Purchase Of PPE | $-16,000 | $-146,000 | $-180,000 | $-321,000 |
| Change In Working Capital | $-1,592,000 | $-489,000 | $-4,330,000 | $1,008,000 |
| Change In Other Working Capital | $-562,000 | $666,000 | $-650,000 | $709,000 |
| Change In Other Current Liabilities | $-1,586,000 | $-1,648,000 | $-1,272,000 | $-1,141,000 |
| Change In Other Current Assets | $80,000 | $244,000 | $22,000 | $5,000 |
| Change In Payables And Accrued Expense | $233,000 | $-445,000 | $-2,331,000 | $2,017,000 |
| Change In Prepaid Assets | $243,000 | $694,000 | $-99,000 | $-582,000 |
| Other Non Cash Items | $1,510,000 | $1,554,000 | $1,357,000 | $1,194,000 |
| Stock Based Compensation | $1,274,000 | $3,135,000 | $4,454,000 | $5,812,000 |
| Asset Impairment Charge | $0 | $951,000 | $0 | - |
| Amortization Of Securities | $-699,000 | $-986,000 | $-1,056,000 | $231,000 |
| Depreciation Amortization Depletion | $139,000 | $1,322,000 | $1,351,000 | $1,347,000 |
| Depreciation And Amortization | $139,000 | $1,322,000 | $1,351,000 | $1,347,000 |
| Depreciation | $139,000 | $1,322,000 | $1,351,000 | $1,347,000 |
| Net Income From Continuing Operations | $-21,085,000 | $-30,157,000 | $-34,101,000 | $-48,588,000 |
| Gain Loss On Sale Of PPE | - | $0 | $302,000 | $-15,000 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $-15,000 |
| Net Business Purchase And Sale | - | - | - | - |
| Purchase Of Business | - | - | - | - |
| Change In Accrued Expense | - | - | - | - |
| Change In Interest Payable | - | - | - | - |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-06-11